These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756 [TBL] [Abstract][Full Text] [Related]
6. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969 [TBL] [Abstract][Full Text] [Related]
7. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment. Zhang J; Guo Y; Fang H; Guo X; Zhao L Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847 [TBL] [Abstract][Full Text] [Related]
10. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Webb MJ; Sangsuwannukul T; van Vloten J; Evgin L; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Chiriboga Yerovi MP; Olin M; Borgatti A; McNiven M; Monga SPS; Borad MJ; Melcher A; Roberts LR; Vile R Nat Commun; 2024 Jun; 15(1):5442. PubMed ID: 38937436 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells. Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978 [TBL] [Abstract][Full Text] [Related]
12. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy]. Hao M; Huang C; Xia N Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820 [TBL] [Abstract][Full Text] [Related]
14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor. Xiang G; Wang M; Wang P; Li R; Gao C; Li Y; Liang X; Liu Y; Xu A; Tang J Viruses; 2024 Jul; 16(8):. PubMed ID: 39205202 [TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model. Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY Cancer Immunol Immunother; 2021 Dec; 70(12):3541-3555. PubMed ID: 33903973 [TBL] [Abstract][Full Text] [Related]
18. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284 [TBL] [Abstract][Full Text] [Related]
19. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling. Armstrong E; Chiu MKL; Foo S; Appleton L; Nenclares P; Patrikeev A; Mohan N; Mclaughlin M; Bozhanova G; Hoebart J; Roulstone V; Patin E; Pedersen M; Kyula J; Ono M; Errington-Mais F; Bell J; Harrington KJ; Melcher A; Jennings V J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060020 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. Vijayakumar G; Palese P; Goff PH EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]